[Ip-health] Brazil's Ministry of Health, PharmaPraxis sign deal to manufacture biologic drugs

Joana Ramos jdr at ramoslink.info
Fri Apr 15 21:19:45 PDT 2011


Others of the public-private partnerships include:

Brazil and its solid PPPs strategy
http://tinyurl.com/42zhmb8

..... The four new partnerships will be established between the local 
Farmanguinhos and  Bristol Myers / Nortec for the production of 
antiretroviral atazanavir (AIDS), the local pharmaceutical company of 
Pernambuco State (Lafepe) and Merck Sharp & Dohme (MSD) aimed to produce 
the antiretroviral Raltegravir (AIDS), the Foundation for Popular 
Medicine (FURP) and Boehringer for the production of Pramipexole 
(Alzheimer's).


http://tribunadonorte.com.br/noticia/governo-federal-faz-ppp-para-a-producao-de-medicamentos/177694
Governo federal faz PPP para a produção de medicamentos

------------- original message----------

http://www.news-medical.net/news/20110407/Brazils-Ministry-of-Health-PharmaPraxis-sign-deal-to-manufacture-biologic-drugs.aspx

News Medical
April 7, 2011
Brazil's Ministry of Health, PharmaPraxis sign deal to manufacture 
biologic drugs

PharmaPraxis, from Axis Biotec, Cryopraxis, Silvestre Labs and 
CellPraxis Group, announces the formalization of an agreement with 
Brazil's Ministry of Health to manufacture biologic drugs.

The Health department of Brazil announced on April 5th, in Brasilia, the 
formalization of four new partnerships with private laboratories for the 
nationalization of the production of drugs for the treatment of AIDS, 
Arthritis <http://www.news-medical.net/health/What-is-Arthritis.aspx> 
and Alzheimers, that currently is imported. The measure foresees to 
reduce an annual deficit of more than US$ 10 billion of the trade 
balance of the health sector and to transfer technology to the Brazilian 
industry. Moreover, the local manufacture of the new drugs must generate 
annual economy of R$ 140 million in the governmental purchases and 
strengthen public politics that aim at to the magnifying of the access 
medicines in the Brazilian Health System named Sistema Unico de Saúde 
(SUS).

Instituto Vital Brazil (IVB), belonging to the government of Rio de 
Janeiro, and the Brazilian pharmaceutical conglomerate, PharmaPraxis, 
will develop a project for the manufacture of the drug Adalimumab, 
indicated for Rheumatoid Arthritis 
<http://www.news-medical.net/health/What-is-Rheumatoid-Arthritis.aspx> 
and Crohn's Disease 
<http://www.news-medical.net/health/What-is-Crohns-Disease.aspx>. The 
new remedies will be added to a list of 25 items that are included in 
the public-private partnership (PPP - parceria público-privada) drawn in 
2009, in accordance with the directive of the Industrial Development 
Organization (PDP - Politica de Desenvolvimento Industrial). The PPPs 
involve nine public laboratories and 20 private industries - ten 
national and ten foreigners. "We can say that with the teams entered in 
field, the model starts to generate products from this year forward," 
disclosed Carlos Gadelha, Secretary of Science Technology and Strategic 
Supplies of the Ministry of Health.

PharmaPraxis is part of Axis Biotec Group, where other biotech companies 
like Cryopraxis, Silvestre Labs and CellPraxis also belong to.

"This is a very important step towards moving into a new biotech 
platform that may take us very far," says Eduardo Cruz, CEO of PharmaPraxis.


---------
Joana Ramos, MSW
Cancer Resources & Advocacy
Seattle WA USA
+1-206-229-2420
http://ramoslink.info/
http://healthwatched.org





More information about the Ip-health mailing list